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Abstract: Diagnosis of complex partial epilepsy is based on the clinical history, and laboratory 
tests, including EEG and neuroimaging studies, corroborate the diagnosis. The goal of epilepsy 
management is to make the patient completely seizure-free without drug-induced side effects, 
even in the patient with refractory complex partial seizures. Frequently this can be accomplished 
by choice of the optimal antiepileptic drug (AED) or a combination of drugs, the use of strategies 
to maximize the effectiveness of drug treatment, or by surgical removal of the seizure focus. 
Currently there are five “classical” first-line AEDs and 11 new AEDs available in the US and 
in many other countries for the treatment of localization-related epilepsy. The current state of 
the evidence is that no AED is clearly superior to other AEDs in the management of refractory 
complex partial seizures. Therefore the choice of which drug to use in an individual patient has 
to be based on other considerations, including the potential adverse reactions that may occur 
in that patient. There are a number of strategies for optimal use of AEDs in the management 
of refractory complex partial seizures. These include verification of the diagnosis of epilepsy 
and classification of specific seizure types, use of monotherapy if possible but polytherapy if 
necessary, starting with a low dose and raising it slowly but, until complete seizure control 
is achieved, pushing to the maximum tolerated dose, changing timing of dosing to reduce 
toxicity, using pharmacokinetic principles to fine-tune AED doses, adjusting dose for drug–drug 
interactions, and never giving up in the pursuit of better seizure control. Resection of the seizure 
focus can be curative in the majority of patients with seizures localized to one mesial temporal 
lobe. Success rates for resection of extratemporal seizure foci are lower. Vagus nerve stimulation 
(VNS) devices result in a significant reduction of seizure frequency in many patients, but patients 
rarely become completely seizure-free as a result of VNS device implantation. Management of 
refractory complex partial seizures continues to improve with the identification of new drugs 
and the development of new approaches to their control and cure.
Keywords: complex partial seizures, localization-related epilepsy, refractory, antiepileptic 
drugs, management
Introduction
Epilepsy is the second most common neurologic disorder after headache. At least 
50 million people in the world suffer from recurrent nonprovoked seizures,1 with 
age-adjusted prevalence rates of 0.2% to 4.1%, depending on the population studied.2 
Fundamentally, there are two types of epilepsy, primary (or idiopathic) generalized 
epilepsy and localization-related epilepsy. Primary generalized epilepsy is considered 
to be genetic in etiology, whereas most localization-related epilepsy is presumed to be 
the result of a cerebral insult, even though the insult cannot be determined in about 
half of all epileptic patients, regardless of age.3–8 However, recent developments in Neuropsychiatric Disease and Treatment 2010:6
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imaging technology have reduced this figure in children and 
young adults with refractory epilepsy, where malformations 
of cortical development have been implicated in about 25% 
of such cases.9–13
Localization-related epilepsy is manifested as one or more 
of three types of seizures: simple partial, complex partial, 
and partial onset with secondary generalization. The specific 
seizure type exhibited by a person with localization-related 
epilepsy is determined by many factors, including choice 
and dose of antiepileptic drugs, and may vary in the same 
individual as a result of changes in both the internal and 
external environment. Localization-related epilepsy accounts 
for about 60%–75% of all epilepsy, and more than half of 
such patients experience complex partial seizures.14,15 Only 
about half of patients with complex partial seizures have 
epilepsy that can be fully controlled with medication; the 
other half have seizures while on antiepileptic drugs, or 
experience significant side effects in order to gain complete 
seizure control. From these statements, it should be appar-
ent that there are more than 7.5 million people in the world 
with refractory complex partial seizures. This article will 
discuss recent advances and strategies in the management 
of refractory complex partial seizures. Seizures are generally 
considered refractory when two are more antiepileptic drugs 
have failed to control the seizures. For research purposes, full 
control has been defined as complete cessation of seizures 
for at least one year.16,17
Epidemiology
The incidence of epilepsy overall is highest in infancy and 
early childhood, and in the elderly.3,8 However, this U-shaped 
distribution is not true in localization-related epilepsy, 
where the incidence is around 20/100,000/year from birth 
to 60 years of age, after which the incidence rises dramati-
cally.8 In a UK study, the incidence of epilepsy (almost all of 
which was localization-related) increased from 76/100,000 in 
people 60–69 years of age to 159/100,000 in those 80 years 
and older.18 This dramatic rise in new onset epilepsy in the 
elderly is largely attributable to cerebrovascular disease and 
degenerative disorders, such as Alzheimer’s disease.19,20 
These numbers may represent an underestimate of the true 
incidence, because in a number of epidemiologic studies 
of epilepsy it is likely that many secondarily generalized 
tonic-clonic seizures have been labeled as generalized, rather 
than partial onset. Furthermore, the incidence of epilepsy is 
clearly higher in developing countries than in industrialized 
countries.21 Nonetheless, it is worthwhile to review further 
what is known about the epidemiology of localization-related 
epilepsy in general and, to the extent possible, of intractable 
complex partial seizures.
Four studies have reviewed the epidemiology of 
localization-related epilepsy.3,14,22–24 Over a 50-year period 
from 1934 to 1984, 880 people were diagnosed with epilepsy 
in Rochester, Minnesota (a predominantly Caucasian middle-
class community). Fifty-seven percent had localization-related 
epilepsy and, of these, two-thirds had complex partial seizures. 
The age-adjusted incidence of individuals with complex 
partial seizures was 16/100,000/year.3 In Southwest France 
the overall incidence of symptomatic localization-related 
epilepsy was 17.1/100,000 but 33.2/100,000 in those aged 
60 or older.23,24 In a Danish study of 1508 consecutive adults, 
73.5% had localization-related epilepsy, and individuals with 
complex partial seizures accounted for 38.2% of all cases.14 
Patients with complex partial seizures accounted for 21.4% 
of the cases in a recent Icelandic study but nearly half of the 
cases were listed as generalized, not otherwise specified.8
The etiology of localization-related epilepsy is highly 
dependent on the age of onset. In all age groups, the etiology 
cannot be determined in more than half (55%–89%) of all 
individuals with epilepsy.15 When etiology can be deter-
mined, congenital anomaly is the largest etiologic category 
in children. In young adults the etiology is unknown in 
more than 75% of patients, but head trauma is the largest 
single etiologic category. In adults aged 35–64 years, 
head trauma, vascular insults, and tumors are all important 
etiologies, whereas cerebrovascular disease and degenera-
tive disorders account for most of the identifiable etiologies 
in localization-related epilepsy in individuals 65 years of 
age or older.19 Advances in neuroimaging techniques have 
improved understanding of the etiology of localization-
related epilepsy. Imaging has allowed the identification of 
the cause of epilepsy in many patients, especially children 
previously considered to have cryptogenic epilepsy. For 
instance, Kuzniecky et al10 reported that 25% of children 
undergoing surgery for medically intractable partial seizures 
had magnetic resonance imaging (MRI) and pathologic find-
ings of cerebral developmental anomalies.
Traumatic brain injury is an important cause of 
localization-related epilepsy, especially in military personnel. 
Traumatic brain injury has become known as the signature 
injury in the Iraq and Afghanistan conflicts because the use of 
body armor and the frequency of blast injuries have allowed 
many soldiers to sustain but survive head injuries. As many 
as 50% of individuals with severe head injuries, especially 
penetrating head injuries, may develop localization-related 
epilepsy, most often within the first two years.25Neuropsychiatric Disease and Treatment 2010:6
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Clinical features
Localization-related epilepsy is manifested as simple partial 
seizures, complex partial seizures, and partial onset seizures 
that become secondarily generalized. All start from a corti-
cal seizure focus. Simple partial seizures remain sufficiently 
localized that there is no impairment of consciousness, and 
the clinical features of the seizure are a reflection of the loca-
tion of the seizure focus. Complex partial seizures spread 
sufficiently to engage portions of the opposite hemisphere, 
and thus result in at least some impairment of consciousness, 
ie, decreased contact with the environment. Secondarily 
generalized seizures start from a cortical focus, but spread 
to the diencephalon and the opposite hemisphere to produce 
complete impairment of consciousness and generalized tonic-
clonic convulsions.
The clinical semiology of complex partial seizures 
depends on the location of the cortical seizure focus. The tem-
poral lobe is the most common site of origin of complex partial 
seizures.26,27 About 80% of patients with localization-related 
epilepsy have temporal lobe seizures.28 Complex partial sei-
zures of mesial temporal origin are frequently associated with 
mesial temporal sclerosis on MRI studies and often begin with 
an aura. Most common are viscerosensory sensations such as 
a rising sensation from the abdomen, or a sense of fear. Déjà 
vu and olfactory sensations are less common. Oro-alimentary 
automatisms (lip smacking, chewing) are common. Head 
turning to the ipsilateral side, manual automatisms on the 
ipsilateral side, or dystonic posturing of the contralateral upper 
extremity may help lateralize the seizure focus.29 Postictal con-
fusion usually lasts at least several minutes, after which there 
is gradual recovery. Typically, the patient is amnestic for events 
during the complex partial seizure. However, many patients 
insist that they are able to perceive their environment during 
complex partial seizures. This likely is because they remember 
the simple partial portion of the seizure, which they perceive 
as the complete seizure. Complex partial seizures of lateral 
or other neocortical temporal origin probably constitute less 
than 10% of temporal onset seizures.27 It has been suggested 
that neocortical temporal lobe seizures most commonly begin 
with sensory illusions or auditory hallucinations, rapid loss 
of contact with the environment, early contralateral dystonic 
posturing without oro-alimentary automatisms, shorter seizure 
duration, and frequent secondary generalization.27 Maillard 
et al30 have described three electrophysiologic subtypes of 
temporal lobe epilepsy.
Frontal lobe onset complex partial seizures are most com-
monly nocturnal. Typically they are abrupt in onset, short in 
duration, and have little or no postictal confusion. Behavior 
can be explosive and bizarre.31 Because of the bizarre 
behavior and frequent difficulty recording unequivocal ictal 
discharges on the EEG (because of large areas of frontal 
cortex inaccessible to surface electrodes), such seizures may 
at times be considered psychogenic nonepileptic seizures. 
However, the stereotyped nature of such seizures in a given 
patient, regardless of how bizarre the behavior is, should 
alert the physician to the likelihood of frontal lobe seizures. 
Characteristics of frontal lobe seizures may vary consider-
ably, depending on location of the seizure focus within 
the frontal lobe. Characteristics of seven different types of 
frontal lobe seizures have been detailed in the International 
Classification of Epilepsies and Epileptic Syndromes.31
Occipital lobe origin complex partial seizures are much 
less common that those of temporal or frontal origin, and are 
characterized by elementary or complex visual hallucinations 
or illusions. Forced blinking or eyelid flutter at the begin-
ning of occipital origin seizures has also been described. The 
clinical features of occipital lobe complex partial epilepsies 
have recently been reviewed.27
Parietal lobe epilepsy is the least common of the 
localization-related epilepsies. Partial onset seizures of 
parietal origin consist of sensory alterations, visuospatial 
disorientation, or apraxias. Seizures arising from or spreading 
to the parietal eye field may result in ipsilateral movement of 
the eyes, in contrast with seizures engaging the frontal eye field, 
which drive the eyes contralateral to the seizure focus.32
Diagnosis of complex partial seizures is based on the 
clinical history, as is true when dealing with all types of 
epilepsy. Fundamentally epilepsy is a clinical diagnosis. Lab-
oratory tests, including EEG and imaging studies, corroborate 
the clinical diagnosis. Table 1 presents characteristic features 
of epileptic seizures, which by history taking enable their 
differentiation from syncopal spells or psychogenic events. 
Table 2 presents a series of questions useful in making the 
diagnosis of an epileptic seizure by history. Deacon et al33 
studied the accuracy of clinical histories taken by epilep-
tologists in the identification of seizures in 88 patients with 
suspected refractory complex partial seizures. They reported 
Table 1 Characteristics of epileptic seizures
• Spontaneous brief episodes of abnormal behavior
• Not time-linked to psychologic precipitants
• Discrete, time-limited events with an identifiable onset and termination
• Predictable evolution of behavior during the seizure
• Progressive recovery of function after the seizure
• Stereotyped from event to eventNeuropsychiatric Disease and Treatment 2010:6
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sensitivity for seizure identification of 96%, but specificity 
of only 50%. Accuracy for complex partial seizures and gen-
eralized seizures was higher than for simple partial seizures. 
Misidentification occurred only with simple partial seizures 
and nonepileptic events.
The history is also critical in the search for the etiology 
of the patient’s epilepsy. It is essential to review the patient’s 
medical history in sufficient detail to identify possible risk 
factors for epilepsy. This is especially important if the 
etiology is one that itself requires treatment and, ideally, can 
be corrected.
The purpose of the neurologic examination in evaluating 
the patient with possible epileptic seizures is two-fold. First, 
the presence of even subtle abnormalities on the neurologic 
examination adds support to the likelihood that the patient’s 
“spells” are epileptic seizures. Second, identification of later-
alizing abnormalities on the neurologic examination allows 
prediction, to some extent, of the location of the epileptic 
focus. This is also done by including specific questions 
regarding seizure semiology when taking the history from 
patients and observers, and looking for such signs on video 
recordings of the seizures either from home videos or on an 
epilepsy monitoring unit (EMU).
Most lateralizing signs are contralateral to the seizure 
focus and include unilateral clonic activity, tonic activity 
in frontal origin seizures (but not temporal origin seizures), 
dystonic posturing, and version (forced deviation of head 
and eyes). Asymmetric tonic posturing producing a “figure-
of-four” sign consists of flexion of the ipsilateral arm and 
rigid extension of the contralateral arm. The last clonic jerk 
is almost always on the side ipsilateral to the seizure focus, 
and unilateral postictal paralysis is always contralateral.29 
Unfortunately, none of these signs is 100% infallible, so 
such signs need to be used together to build a confident 
picture of lateralization, and need to be considered only as 
suggestive of the likely lateralization of seizure origin. Chung 
et al34 recently described a highly reliable sign with which 
to differentiate between epileptic seizures and psychogenic 
nonepileptic events. Almost all (94%) patients with epileptic 
seizures keep their eyes open during the seizure, whereas 
almost all (99%) patients with nonepileptic events close their 
eyes during the seizure.
The electroencephalogram (EEG) is an essential element 
in the evaluation of patients with possible epilepsy, but 
finding epileptiform discharges on the EEG is not essential 
for the diagnosis. Even in adults with established epilepsy, 
only 29% to 55% have interictal spikes on their first EEG, 
although 80% to 90% will eventually show interictal spikes 
on repeated EEG examinations.35 In localization-related 
epilepsy, finding an interictal spike focus, especially in the 
anterior or midtemporal regions, indicates cortical irritabil-
ity or hyperexcitability, and strongly suggests the presence 
of a seizure focus in that location. Focal slowing, indica-
tive of underlying structural damage, may also localize a 
seizure focus, but is much less specific than a spike or sharp 
wave focus. The likelihood of observing interictal spikes 
or sharp waves can be increased significantly by recording 
30 minutes of sleep; other EEG activation procedures do 
not often reveal spikes or sharp waves not present during 
the routine recording.
Ictal discharges on the EEG are usually observed on an 
EMU, except on infrequent occasions when a seizure is cap-
tured on a routine EEG. Seizures recorded on EMU have the 
advantage that behavior recorded on video (seizure semiol-
ogy, as described above) can be correlated with EEG changes. 
Almost all patients with localization-related epilepsy who are 
evaluated on an EMU have medically refractory seizures, so 
studies have not differentiated between ictal EEG findings in 
patients with medically responsive and medically refractory 
seizures. Ictal discharges recorded from scalp electrodes can 
vary in appearance, beginning with low-voltage fast activity 
or rhythmic slowing, or sometimes flattening of the EEG. 
There may be a heralding spike at onset, and interictal spikes 
may increase or decrease in frequency before a partial onset 
seizure. Onset can be quite focal in onset, begin simultane-
ously over most of one hemisphere, or begin diffusely over 
most electrodes. Characteristically, there is an evolution of 
the EEG changes, often with an increase in amplitude and 
decrease in frequency as the seizure progresses and, if the 
Table 2 Historical information helpful for diagnosis of epilepsy
•   Detailed second-by-second description of the spell – what happened 
first, second, etc?
• Loss of consciousness? When in relation to motor activity?
•   Bilateral involvement before loss of consciousness (may occur in 
frontal lobe seizures)?
• Convulsive activity? What and where?
•   Tongue biting, incontinence, postictal muscle soreness (may also occur 
with convulsive syncope or psychogenic events)?
• Stare, automatisms, of what type?
• Nature of onset, cessation?
• Duration of each behavior (ictal events, postictal)?
•   Any elements suggesting syncope (pallor, diaphoresis, dimming of vision, 
rapid recovery)?
•   Any elements suggesting psychogenic event (variable behavior, 
prolonged duration, brief pauses during “convulsive” activity,  
eyes closed during the event)?Neuropsychiatric Disease and Treatment 2010:6
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seizure has begun focally, spread to engage other cortical 
areas. As a generalization, seizures that impair conscious-
ness exhibit associated EEG changes in scalp recordings, 
although frontal lobe origin complex partial seizures may 
not. Seizures that do not impair consciousness (simple partial 
seizures) may not exhibit EEG changes. Only 21%–61% 
exhibit a scalp EEG correlate.36–38 This is because the neu-
ronal hypersynchronous discharges of the simple partial 
seizure may remain sufficiently localized that EEG changes 
are attenuated between cortex and scalp. The minimal size of 
a hypersynchronous cortical discharge that can be detected 
as a spike by scalp electrodes is 6 cm2,39 but a 10 cm2 area of 
activation is much more likely to be detected on the surface 
as a spike or ictal rhythm, and synchronous activation of 
10–20 cm2 of gyral cortex is common.40,41
Neuroimaging has become of increasing importance in 
the evaluation of refractory complex partial seizures with 
the development of high resolution MRI, new imaging pro-
tocols, and nuclear medicine procedures, such as positron 
emission tomography scanning, and ictal and interictal single 
positron emission computerized tomography (SPECT). More 
recently, subtraction ictal single-photon emission tomogra-
phy coregistered to magnetic resonance imaging (SISCOM) 
has enhanced the power of SPECT. These new techniques 
have led to significant improvement in the ability to identify 
the ictal onset zone. For instance, it has been suggested that 
SISCOM can reveal areas of hyperperfusion or hypoperfu-
sion in up to 80% of patients with intractable seizures and 
may also predict operative outcome.42,43
MRI continues to be the most sensitive and specific imag-
ing technique for localization-related epilepsy. Detection of 
abnormalities (atrophy, increase in signal) can be enhanced 
by use of specific “seizure” protocols, which orient the image 
in the oblique coronal plane to best visualize the amygdalar 
and hippocampal structures. The introduction of increasingly 
powerful magnets has improved resolution as well. Hippo-
campal atrophy can best be seen using T1- weighted imaging, 
whereas increased signal brightness can best be appreciated 
with T2-weighted imaging or fluid-attenuated inversion 
recovery (FLAIR) sequences. Quantitative volumetric studies 
can be helpful for the detection of hippocampal atrophy, but 
are labor intensive and only available in a few centers.
Medical treatment
The goal of epilepsy management is to make the patient 
completely seizure-free. This is the goal of management of 
refractory complex partial seizures as well, and not infre-
quently can be achieved by the choice of the optimal AED 
or a combination of drugs, the use of strategies to maximize 
the effectiveness of drug treatment, or by surgical removal 
of the seizure focus.
Currently there are five “classical” first-line AEDs and 11 
new AEDs available in the US and in many other countries 
(Table 3). Unfortunately, few direct comparisons provide data 
with which to determine the relative effectiveness of these 
drugs. Two US Veterans Administration Cooperative studies 
compared the classical AEDs in the treatment of new onset 
partial onset seizures in adults, using a randomized double-
blind design. The principal outcome measure was retention 
on the drug (ie, the drug was sufficiently effective and suf-
ficiently free of side effects that the patient and investigator 
agreed to continue that drug). In the first study, phenytoin 
(PHT) and carbamazepine (CBZ) were superior to pheno-
barbital (PB) and primidone (PRIM) in patients with mostly 
simple and/or complex partial seizures.44 In the second study 
there was no difference in retention, but CBZ was superior 
to divalproex sodium in the treatment of complex partial sei-
zures in four of five secondary measures.45 A large, unblinded, 
randomized, pragmatic trial in hospital-based outpatients in 
the United Kingdom identified 1721 patients for whom CBZ 
was considered standard treatment (ie, those with partial 
onset seizures) and randomized them to treatment with one 
of five AEDs: CBZ, gabapentin (GBP), lamotrigine (LTG), 
oxcarbazepine (OXC), or topiramate (TPM). Two primary 
outcome measures were used, ie, time to treatment failure 
and time to 12-month remission. LTG was significantly better 
than CBZ, GBP, and TPM and had a nonsignificant advantage 
over OXC in the time to treatment failure measure, but CBZ 
was significantly better than GBP and had a nonsignificant 
advantage over LTG, TPM, and OXC in time to 12-month 
remission.46 About 50% of patients reported side effects at 
Table 3 AeDs available for partial onset seizures
Classical AEDs New AEDS
phenobarbital felbamate
phenytoin gabapentin
primidone lamotrigine
carbamazepine topiramate
valproate tiagabine
levetiracetam  
oxcarbazepine   
zonisamide  
pregabalin  
lacosamide  
vigabatrin
Notes: Drugs are listed in the order of approval in the US.
Abbreviation:  AeDs, antiepileptic drugs.Neuropsychiatric Disease and Treatment 2010:6
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some point in the study, but differences among AEDs were 
not large. Tiredness, headache, and fatigue were common 
symptoms for all drugs. Depression, disturbance of memory, 
and various psychiatric symptoms were also common, 
particularly with TPM. Rash was most common with CBZ 
and OXC, and least common with LTG. No multiple drug 
comparison trials have been done in patients with refractory 
complex partial seizures. A joint committee of the American 
Academy of Neurology and the American Epilepsy Society 
reviewed seven new AEDs (GBP, LTG, TPM, tiagabine 
[TGB], OXC, levetiracetam [LEV], and zonisamide [ZNS]) 
and considered all to be appropriate for adjunctive treatment 
of refractory partial seizures in adults.47 Multiple individual 
drug comparisons have failed to show consistent superior-
ity of the new AEDs over the classical AEDs or of one new 
AED over another in the treatment of either new onset or 
refractory partial onset seizures. Wilby et al conducted a 
systematic review of 212 studies of newer drugs for epilepsy 
(GBP, LTG, LEV , OXC, TGB, TPM, and vigabatrin). They 
concluded that there is “… little good-quality evidence from 
clinical trials to support the use of newer monotherapy or 
adjunctive therapy AEDs over older drugs, or to support the 
use of one newer AED in preference to another. In general, 
data relating to clinical effectiveness, safety and tolerability 
[have] failed to demonstrate consistent and statistically sig-
nificant differences between the drugs”.48
The current state of the evidence, therefore, is that none 
of the presently available AEDs is clearly superior to other 
AEDs in the management of refractory complex partial 
seizures. Therefore, the choice of which drug to use in an 
individual patient has to be based on other considerations, 
including previous success or failure of a given drug, cost, 
and side effect profile of the drug matched to individual 
patient characteristics (Table 4). For instance, drugs associ-
ated with significant weight gain potential, valproate (VPA) 
and pregabalin in particular, might best be avoided in already 
overweight individuals. Drugs with significant potential for 
cognitive impairment (eg, TPM) should be used with cau-
tion in individuals with intellectually demanding occupa-
tions. AEDs that can be taken once daily (eg, PHT, ZNS, 
TPM, and extended-release forms of CBZ, LTG, and LEV) 
have a clear advantage in patients for whom denial of their 
epilepsy can frequently lead to poor compliance. In women 
of child-bearing potential, AEDs with a significant risk of 
teratogenicity (eg, VPA) should be avoided.
There are a number of strategies for the optimal use 
of AEDs in the management of refractory complex partial 
seizures (Table 5). Diagnosis and classification of the 
seizure type and choice of AEDs have been discussed 
above. In the medically refractory patient, a review of 
previously tried AEDs is essential. Was the drug tried 
at maximal tolerated doses and given for long enough to 
achieve pharmacokinetic and pharmacodynamic steady 
states and to allow resolution of early treatment side effects, 
such as sedation and gastrointestinal upset? All too often 
potentially effective AEDs are abandoned because initial 
doses are so high or the rate of titration so fast that early 
side effects develop which could have been avoided had 
the drug been started more slowly. In the medically refrac-
tory patient, rapid titration of a new-to-the-patient AED 
is rarely necessary; the patient has had refractory seizures 
for a long time and a few days or even weeks spent slowly 
increasing the dose can often make the difference between 
success and failure.
Table 4 Factors to consider when choosing an AED for a specific 
patient
Adverse reactions AED(s)
Hirsutism, gum hyperplasia PHT
Alopecia, tremor vPA
weight gain vPA, GBP, PGB
weight loss FBM, TPM, ZNS
Hyponatremia CBZ, OXC
Teratogenicity vPA
Compliance issues AED(s)
Once-daily dosing possible  PB, PHT, TPM, ZNS  
extended-release AeDs
Abbreviations: AeDs, antiepileptic drugs; CBZ, carbamazepine; FBM, felbamate; 
GBP, gabapentin; OXC, oxcarbazepine; PB, phenobarbital; PBG, pregabalin; PHT, 
phenytoin; TPM, topiramate; vPA, valproate; ZNS, zonisamide.
Table 5 Strategies for optimizing management of refractory 
complex partial seizures
• verify the diagnosis of epilepsy and determine the etiology if possible
•   review the patient’s seizure descriptions to be sure of their correct 
classification
• Match choice of AED to the seizure type(s) and to the specific patient
• Use monotherapy if possible
• Use polytherapy if necessary
•   when adding an AeD start low and go slow, but, if necessary push to 
the maximum tolerated dose
• Consider changing the timing of dosing to reduce toxicity
• Use pharmacokinetic principles to fine-tune the dose
• Adjust doses for drug–drug interactions
• Do not give up
Abbreviation: AeD, antiepileptic drug.Neuropsychiatric Disease and Treatment 2010:6
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If possible, seizure control with a single agent is preferable. 
This avoids the potential for drug–drug interactions, is gener-
ally less expensive, and may result in better seizure control.49 
Therefore, ideally, each of the first-line AEDs available for 
management of partial onset seizures (ie, all current first-line 
drugs except ethosuximide) which are appropriate for the spe-
cific patient, should be tried before considering polytherapy. 
Although one drug may fail as monotherapy, another may 
succeed, even when the two drugs have similar profiles in 
animal models and share the same mechanism of action.50 For 
example, when PHT and CBZ (both stabilizers of the sodium 
channel) were compared in three crossover trials in the treat-
ment of complex partial seizures, some patients responded 
much better to one drug than to the other, even though there 
were no differences in the overall efficacy of the two drugs.51–53 
However, sequential trials of AEDs as monotherapy must not 
leave the patient without drug treatment. A useful approach 
(Figure 1) is to increase the dose of a single AED to that which 
is maximally tolerated. If seizure control is not achieved, a 
second AED should be added and the dose should be raised 
gradually to mid-therapeutic range. Transient dose-related side 
effects are far less dangerous to the patient than an increase 
Seizures continue 
on one (#1) AED 
Push to maximum 
tolerated dose 
Add another (#2) 
AED, titrate to mid-
therapeutic dose
Szs. persist 
Maintain on AED regimen, 
consider withdrawal of #1 AED 
Szs. stop 
Gradually taper #1 
AED. Wait until 
complete cleared. 
Then add another 
(#3) AED, titrate to 
mid-therapeutic
dose
Push to maximum 
tolerated dose 
Szs. persist  
Szs. stop 
Maintain on AED regimen, 
consider withdrawal of #1 AED 
Szs. stop 
Maintain on AED regimen, 
consider withdrawal of #2 AED 
Szs. stop 
Maintain on AED regimen, 
consider withdrawal of #2 AED 
Szs. persist  
• Continue algorithm with additional AEDs, or 
• Consider resective surgery, or, if not a candidate, 
• Consider VNS or clinical trial of experimental AEDs 
Szs. persist  
Figure 1 Algorithm for successive monotherapy trials in a patient with uncontrolled seizures. This approach allows testing the efficacy and tolerability of AEDs as monotherapy 
without subjecting the patient to the risk of increased seizures that could occur if an existing drug is tapered simultaneously with the uptitration of an additional drug. Dose-related 
side effects are in general much less dangerous than the risk of additional seizures and can be treated by lowering the dose of the offending drug.
Abbreviations: AeD, antiepileptic drug; Szs, seizures;  vNS, vagal nerve stimulator.Neuropsychiatric Disease and Treatment 2010:6
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in seizure frequency or severity that could occur if the dose 
of the first drug is lowered before the dose of the second drug 
is increased. If there is at least some therapeutic response to 
the second drug, the dose can be escalated further until either 
seizure control is achieved or unacceptable side effects appear. 
If seizure control is achieved, the dose of the first drug then 
may be gradually tapered to determine if seizure control can 
be maintained with monotherapy. If there is no response, the 
procedure can be repeated with yet another AED. In this way 
a series of AEDs used as monotherapy and as dual therapy 
can be screened to identify the optimal drug or combination 
of drugs for a particular patient.50 Although combination 
therapy has little additional benefit in most patients with new 
onset epilepsy,17 it may have significant benefit in patients 
with refractory complex partial seizures. At least one-third 
of patients with new onset epilepsy and more than half with 
complex partial seizures will require more than one drug to 
achieve seizure control.
The use of more than one AED in a patient creates the 
potential for pharmacokinetic drug–drug interactions, as 
does the use of AEDs in patients taking drugs for other 
indications. Most of the “classical” AEDs have the poten-
tial for either induction or inhibition of cytochrome P450 
isozymes; fortunately many of the newer drugs do not. 
Table 6 provides a list of currently available AEDs and 
their potential for drug–drug interactions. Table 7 provides 
a list of drugs other than AEDs which may interact with 
AEDs. These potential interactions have to be considered 
whenever a patient is taking more than one drug, and 
may necessitate adjusting the dose of one AED if others 
are also being prescribed, or if the patient is taking other 
drugs as well as AEDs. Grapefruit inhibits CYP3A4, a 
P450 isozyme important in the metabolism of some of the 
benzodiazepines, CBZ, TGB, and ZNS.54
It is essential in the management of the patient with 
refractory complex partial seizures to push the dose(s) of the 
AED or combination of drugs as high as necessary to achieve 
seizure control without producing unacceptable side effects. 
Animal and human studies show that seizure control is cor-
related with AED concentrations.50 The therapeutic range for 
all currently available AEDs is no more than an empirically-
derived probability statement, with the low end being the 
serum concentration at which efficacy is seen in most but not 
all patients and the high end being the concentration at which 
toxicity is seen in most but not all patients. These therapeutic 
ranges have been determined empirically in a nonsystematic 
fashion. There has never been a formal prospective determi-
nation of the median effective dose or median toxic dose of 
any AED in human patients. Therefore, the effective dose and 
the toxic dose of an AED must be determined empirically for 
individual patients. The therapeutic range should only serve 
as a rough guide to dosing, but should never inhibit upward 
titration of the dose of an AED if the patient is tolerating the 
drug well and continues to have seizures.
The pharmacokinetic characteristics of the drug must be 
considered when increasing the dose of an AED. Most AEDs 
exhibit first-order kinetics within the therapeutic range, so 
that there is a linear relationship between dose and serum 
concentration (Figure 2). However, three current AEDs 
(CBZ, VPA, GBP) exhibit a curvilinear relationship between 
dose and concentration such that there is a decrease in the 
concentration response as the dose is increased. On the other 
hand PHT exhibits Michaelis-Menten (saturation) elimina-
tion kinetics within the therapeutic range, and thus there 
is an increase in the concentration response as the dose is 
increased. Small increases in dose result in large increases in 
concentration. Because PHT is still used by many physicians 
(including non-neurologists) it is important to understand 
how to make adjustments of the dose to achieve maximum 
seizure control whilst avoiding toxic side effects. At the high 
Table 6 Potential drug–drug interactions of AeDs caused by 
microsomal P450 induction or inhibition
Inducers Inhibitors No effect
carbamazepine felbamate gabapentin
phenobarbital valproate lacosamide
phenytoin zonisamide  
  (min. phenytoin)
lamotrigine
primidone levetiracetam
oxcarbazepine (estrogens,  
  dihydropyridines, cyclosporin)
pregabalin  
tiagabine
vigabatrin  
zonisamide (min. carbamazepine)
   topiramate 
Abbreviation: AeDs, antiepileptic drugs.
Table 7 Potential effects of some nonantiepileptic drugs on AeD 
elimination via microsomal P450 enzyme
Inducers Inhibitors  
alcohol allopurinol erythromycin
nicotine chloramphenicol grapefruit
oral contraceptives cimetidine isoniazid, PAS
other steroids coumarin phenylbutazone
phenothiazines diltiazem propranolol
rifampin    (and other CCBs)  
disulfiran
propoxyphene  
sulfonamides
Abbreviations: AeD, antiepileptic drug; CCBs, calcium channel blockers; PAS, 
para-aminosalicylic acid.Neuropsychiatric Disease and Treatment 2010:6
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end of the therapeutic range PHT doses should be adjusted 
by 10 mg increments to avoid excessive increases in serum 
concentration and consequent toxic side effects.50 Table 8 
provides predicted increases in PHT serum concentration 
following 10 mg increases in the daily dose for low, mid, and 
high serum concentrations. 10 mg increments in the oral dose 
can be achieved for any dose of 180 mg and above by using 
a combination of the available 100 mg and 30 mg capsules.
Therapeutic drug monitoring can be useful in the manage-
ment of refractory complex partial seizures. It is particulary 
useful in helping to determine which drug is causing adverse 
effects if a patient is taking two or more AEDs. It may also be 
useful in some circumstances to verify compliance. Finally, 
serum concentrations are very useful for fine-tuning PHT 
dosing, especially in the intensive care setting where a patient 
may be receiving a multitude of drugs, but also in the outpa-
tient setting, as described above. Peak concentrations are most 
useful in assessing toxicity; trough levels are most helpful in 
assessing compliance. Serum concentrations are readily and 
rapidly available for most of the classical AEDs (PB, PHT, 
CBZ, VPA) but not as easily obtainable for most of the newer 
AEDs. Furthermore, therapeutic ranges are not nearly as well 
established for the newer AEDs, so therapeutic monitoring is 
less useful in the management of these drugs.
Sometimes seizure control can be achieved by chang-
ing the timing of AED dosing. As a generalization, an 
AED should not be given less often than at least once a 
half-life to avoid excessive fluctuations in peak and trough 
concentrations. For rapidly absorbed drugs (those without 
extended-release formulations) the peak concentration (Tmax) 
PHT
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CBZ, GBP,
VPA 
LEV, LTG, 
LCM. PGB, 
PB, TGB, 
TPM, ZNS
Figure 2 effect of dose on elimination kinetics of AeDs. 
For most AeDs the relationship between AeD dose and concentration is linear. However, valproate (because of saturation of serum protein-binding sites), gabapentin (because 
of saturation of L-amino acid transport enzymes in the intestine) and carbamazepine (because of autoinduction of its own metabolizing p450 isozymes) exhibit a nonlinear 
relationship between dose and serum concentration. The higher the dose, the less increase in concentration per unit dose is achieved. Phenytoin exhibits Michaelis-Menten 
(saturation) kinetics. Because of the saturation of the microsomal p450 isozymes responsible for phenytoin metabolism, the higher the dose the greater the increase in serum 
concentration per unit dose. Figure modified and updated from Kriel and Cloyd.66
Abbreviations: AeD, antiepileptic drug; CBZ, carbamazepine; GBP, gabapentin; Lev, levetiracetam; LTG, lamotrigine; LCM, lacosamide; PGB, pregabalin; PHT, phenytoin; 
PB, phenobarbital; TGB, tiagabine; TPM, topiramate; vPA, valproate; ZNS, zonisamide.
Table 8 Predicted increase in serum phenytoin concentration 
following a 10 mg increase in daily dose50
Daily dose 200 mg 300–400 mg 500 mg
Initial concentration Effect of a 10 mg change in dose
10 µg/mL 1.5 µg/mL 1.0 µg/mL 0.5 µg/mL
15 µg/mL 3.0 µg/mL 1.5 µg/mL 0.75 µg/mL
20 µg/mL 6.0 µg/mL 3.0 µg/mL 1.5 µg/mL
Notes: *By extrapolating between concentrations, this table can be used to adjust 
the maintenance phenytoin dose for most patients for whom a steady-state phe-
nytoin concentration is available. Some individuals, however, are hypometabolizers of 
phenytoin and some are hypermetabolizers. For such patients it may be necessary to 
shift to the left or right column, respectively, even if the patient is taking 300–400 mg/day. 
The table was derived from a nomogram for adjustment of phenytoin maintenance 
doses created by rambeck et al.67Neuropsychiatric Disease and Treatment 2010:6
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occurs about 1.0 to 1.5 hours after oral administration. If the 
patient experiences post-dose toxicity, this can be reduced 
by using smaller doses more frequently throughout the day. 
However, if the drug has a long-half life, it may be possible to 
give the entire dose immediately before bedtime, so that the 
peak concentration occurs when the patient is in slow-wave 
sleep. Drugs that cause insomnia (felbamate and sometimes 
LTG), however, are best taken early in the day. It is clear 
that compliance is improved by once or twice a day dosing, 
and is reduced if AED dosing is more frequent,55 and this 
must also be considered in any dosing strategy.
Surgical strategies for the management of refractory 
complex partial seizures will be discussed below. However, 
if surgery is not an option, it is important to continue to try to 
achieve seizure control with AEDs. Do not give up. There are 
now 16 AEDs available in the US for treatment of refractory 
complex partial seizures. This means there are 120 potential 
two-drug combinations and many more three drug combina-
tions. Perseverance alone can sometimes lead to successful 
control of refractory complex partial seizures. Luciano and 
Shorvon56 recently reported the result of 265 drug additions 
in 155 adult patients with chronic pharmacoresistant epilepsy. 
Twenty-eight percent eventually became seizure-free, but 
only 17% stopped having seizures after the addition of only 
one AED. The other 11% required trials of two, three, or more 
additional AEDs to achieve seizure freedom. Similar results 
have been reported by Callaghan et al.57
Surgical strategies
Surgical intervention has to be a consideration in the man-
agement of refractory complex partial seizures. Currently 
available interventions include resection of the seizure focus, 
multiple subpial transection when the seizure focus is in 
eloquent cortex, destruction of the seizure focus by gamma 
knife, and implantation of a VNS. Deep brain stimulation and 
stimulation of the seizure focus are under study, but these are 
not yet approved interventions.
Patients should be considered for resective surgery when 
the seizure focus appears to be well localized and has a solo 
focus. This is best predicted by the seizure semiology at 
onset, as discussed above. The ideal candidate for resective 
surgery is the patient with refractory complex partial sei-
zures whose semiology suggests mesial temporal onset, who 
has failed an adequate trial of at least two or three AEDs, 
and who exhibits mesial temporal sclerosis on MRI. In such 
patients, success rates of 70%–90% for selective amygdalo-
hippocampectomy or temporal lobectomy can be expected 
in the hands of an experienced surgeon. Téllez-Zentano 
et al58 recently reviewed the long-term outcome of surgical 
procedures for epilepsy. Overall the median proportion of 
long-term seizure-free patients was 66% for temporal lobe 
resections, 46% for occipital and parietal resections, and 
27% for frontal lobe resections. Multiple subpial transec-
tions only resulted in long-term seizure freedom in 16%. 
Successful destruction of the seizure focus with gamma 
radiation in patients with mesial temporal epilepsy has been 
reported in several recent series, with long-term success 
rates comparable with those for resective surgery. However, 
the mean time to seizure control has been 12 months, in 
contrast with immediate seizure freedom following open 
surgery.59–61
When medical treatment options have been exhausted and 
resective surgery is not possible (usually because of bilateral 
mesial temporal-independent seizure foci), implantation of 
a VNS should be considered in the patient with medically 
refractory complex partial seizures. Overall response rates of 
35% to 45% have been reported,62–64 but few patients become 
completely seizure-free, and almost all remain on AEDs. 
Nonetheless, a VNS can be of great benefit to some patients 
with refractory complex partial seizures. High stimulation 
parameters are more effective than low stimulation param-
eters, but result in more adverse reactions.65
Conclusion
Epilepsy is the third most common neurologic disorder in 
incidence, but the second most common neurologic disor-
der in prevalence. Because it affects all ages and because 
of the social stigma attached to epilepsy in many cultures, 
it has a disproportionately high impact on the quality of 
life of the patients it affects. Refractory complex partial 
seizures affect at least 7.5 million up to perhaps as many 
as 10 million people worldwide. Many advances have been 
made in the management of complex partial seizures, but 
one-third of afflicted patients continue to have uncontrolled 
seizures. Fortunately, there are a number of strategies that 
can improve control of such seizures, as discussed above, and 
a number of new approaches to management that are likely 
to come to fruition over the next several decades and result 
in significant improvement in the management of complex 
partial seizures.
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